The efficacy and safety of prostatic urethral lift as a minimally invasive therapeutic modality to treat lower urinary tract symptoms while maintaining sexual function in patients with benign prostatic hyperplasia: A systematic review and meta-analysis of randomized controlled trials

被引:1
|
作者
Warli, Syah Mirsya [6 ]
Ikram, Muhammad Fahmi [1 ,3 ]
Sarumpaet, Raja Gerald [3 ]
Tala, Zaimah Zulkarnaini [2 ,4 ]
Putrantyo, Ignatius Ivan [5 ]
机构
[1] Univ Sumatera Utara Hosp, Univ Sumatera Utara, Dept Urol, Medan, Indonesia
[2] Univ Sumatera Utara, Haji Adam Malik Gen Hosp, Fac Med, Dept Surg, Medan, Indonesia
[3] Univ Sumatera Utara, Fac Med, Medan, Indonesia
[4] Univ Sumatera Utara, Fac Med, Dept Nutr, Medan, Indonesia
[5] Univ Indonesia, Haji Adam Malik Gen Hosp, Fac Med, Dept Urol, Medan, Indonesia
[6] Univ Sumatera Utara, Haji Adam Malik Gen Hosp, Fac Med, Dept Surg, l. Bunga Lau.17, Medan, Indonesia
关键词
Benign Prostatic Hyperplasia; Lower Urinary Tract Symptoms; Prostathic Urethral Lift; Quality of Life; Sexual Function; QUALITY-OF-LIFE; TRANSURETHRAL RESECTION; EPIDEMIOLOGY; MULTICENTER; DYSFUNCTION; SECONDARY; RISK; MEN;
D O I
10.4081/aiua.2024.12066
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Benign Prostatic Hyperplasia (BPH) is prevalent among elderly men, necessitating focused attention. The Prostatic Urethral Lift (PUL) procedure, a minimally invasive intervention, has emerged as a promising option for BPH management. It has shown remarkable results in ameliorating Lower Urinary Tract Symptoms (LUTS), enhancing quality of life, and preserving sexual function. This study aims to evaluate the effectiveness and safety of PUL in BPH patients. Methods: Key databases (MEDLINE, Cochrane CENTRAL, ScienceDirect, EBSCO, Google Scholar) were systematically searched using pertinent terms related to PUL and BPH. Following the PRISMA checklist, we considered only Randomized Controlled Trials studies (RCTs) from 2013 to 2023. The assessment focused on LUTS, Quality of Life, sexual function, and Adverse Events, within three months. Follow-up post -treatment mean values compared with controls (Sham) and the improvement from baseline to post -treatment follow-up duration were considered. Statistical analysis and risk of bias evaluation were conducted using Review Manager 5.4.1, presenting results as difference of mean values (MD) and Risk Ratios (RR). Results: A meta -analysis with a Random Effects Model of 7 RCTs involving 378 confirmed BPH patients demonstrated significant improvements in the PUL arm including International Prostate Symptom Score (IPSS) (MD 5.51, p < 0.0001), maximum urinary flow rate (Q(max)) (MD 2.13, p = 0.0001), BPH Impact Index (BPHII) (MD 2.14, p = 0.0001), and IPSS-QoL (MD 1.50, p < 0.0001), without significant increase of Adverse Events (RR 1.51; p = 0.50). Positive outcomes were observed in sexual function variables and post -void residual measurements when post -treatment values were compared to baseline. Conclusions: PUL holds advantages over control interventions, providing encouraging prospects for BPH management. This study underscores the need for further exploration of PUL's efficacy and safety in BPH patients.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Efficacy and safety of a hexanic extract of Serenoa repens (Permixon®) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies
    Vela-Navarrete, Remigio
    Alcaraz, Antonio
    Rodriguez-Antolin, Alfredo
    Minana Lopez, Bernardino
    Fernandez-Gomez, Jesus M.
    Angulo, Javier C.
    Castro Diaz, David
    Romero-Otero, Javier
    Brenes, Francisco J.
    Carballido, Joaquin
    Molero Garcia, Jose Ma
    Fernandez-Pro Ledesma, Antonio
    Cozar Olmos, Jose Manuel
    Manasanch Dalmau, Jose
    Subirana Cachinero, Isaac
    Herdman, Michael
    Ficarra, Vincenzo
    BJU INTERNATIONAL, 2018, 122 (06) : 1049 - 1065
  • [32] Phosphodiesterase-5 Inhibitors for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis
    Liu, Liangren
    Zheng, Shuo
    Han, Ping
    Wei, Qiang
    UROLOGY, 2011, 77 (01) : 123 - 129
  • [33] Randomized Controlled Trial to Assess the Efficacy of the Combination Therapy of Alfuzosin and Tadalafil in Patients with Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
    Kumar, Santosh
    Kondareddy, Chilekampalli
    Ganesamoni, Raguram
    Nanjappa, Bhuvanesh
    Singh, Shrawan K.
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2014, 6 (01) : 35 - 40
  • [34] Comparative Efficacy of Different Drugs for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Bayesian Network Meta-Analysis
    Fan, Zhinan
    Shi, Hongjin
    Zhang, Jinsong
    Wang, Haifeng
    Wang, Jiansong
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [35] Impact on Sexual Function of Endoscopic Enucleation vs Transurethral Resection of the Prostate for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis
    Liu, Yuqing
    Cheng, Yinchu
    Zhuo, Lin
    Liu, Ke
    Xiao, Chunlei
    Zhao, Rongsheng
    Lu, Jian
    Ma, Lulin
    JOURNAL OF ENDOUROLOGY, 2020, 34 (10) : 1064 - 1074
  • [36] The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia: a systematic review and meta-analysis
    Li, Yao
    Ma, Jie
    Qin, Xin-Hua
    Hu, Chuan-Yi
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2022, 11 (03) : 313 - 324
  • [37] Safety and efficacy of an α1-blocker plus mirabegron compared with an α1-blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: a systematic review and network meta-analysis
    Herschorn, Sender
    Tarcan, Tufan
    Jiang, Yuan-Hong
    Chung, Eric
    Abdul Hadi, Farid
    Steup, Achim
    Sumarsono, Budiwan
    NEUROUROLOGY AND URODYNAMICS, 2024, 43 (03) : 604 - 619
  • [38] The efficacy and safety of desmopressin acetate applied for nocturia in benign prostatic hyperplasia patients: A systematic review and meta-analysis
    Wang, Qihua
    Alshayyah, Rami
    Yang, Bo
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2022, 14 (03) : 155 - 162
  • [39] Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis
    Sun, Kai
    Sun, Fengze
    Yao, Huibao
    Zhang, Dongxu
    Wu, Gang
    Wang, Tianqi
    Wang, Jipeng
    Wu, JiTao
    AMERICAN JOURNAL OF MENS HEALTH, 2020, 14 (06)
  • [40] Outcomes and complications of naftopidil versus tamsulosin for elderly men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review and meta-analysis
    Chai, Yumeng
    Zhou, Zhongbao
    Cui, Yuanshan
    Che, Xuanyan
    Zhang, Yong
    ANDROLOGIA, 2021, 53 (09)